Endometriosis biomarkers
AssigneeProteomics International (IP) Pty Ltd
InventorsRichard Lipscombe, Scott Bringans, Tammy Casey
Life of this patent
Estimating the term…
Abstract
A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from Table 1, 2 or 3 in a sample from a subject, where in the at least one protein may be selected from the list comprising: Beta-Ala-His dipeptidase, Apolipoprotein L1, Methanethiol oxidase, Vitamin K-dependent protein S, von Willebrand factor, Plasminogen, Selenoprotein P, Protein disulfide-isomerase A6 and Inter-alpha-trypsin inhibitor heavy chain H3, and (b) using the expression level to determine whether the subject has endometriosis.
Claims15
A method of treating a subject for endometriosis, comprising the steps of:
- (a) assessing an expression level of at least one protein, selected from the group consisting of Complement factor H-related protein 2, Beta-Ala-His dipeptidase, Sex hormone-binding globulin, Corticosteroid-binding globulin, Apolipoprotein L1, Catalase, C4b-binding protein alpha chain, Carbonic anhydrase 2, Superoxide dismutase [Cu—Zn], Peroxiredoxin-1, Annexin A1, Methanethiol oxidase, Bisphosphoglycerate mutase, Rho GDP-dissociation inhibitor 2, C4b-binding protein beta chain, Protein S100-A8, ADAMTS-like protein 2, Vitamin K-dependent protein S, Peroxiredoxin-2, Beta-2-glycoprotein 1, Hepatocyte growth factor activator, Annexin A3, Endoplasmic reticulum chaperone BiP, Flavin reductase (NADPH), Fibrillin-1, Annexin A5, Profilin-1, Afamin, von Willebrand factor, L-lactate dehydrogenase A chain, Plasminogen, Selenoprotein P, Proteoglycan 4, Hyaluronan-binding protein 2, Protein disulfide-isomerase A6, Coactosin-like protein, Complement component C9, Coagulation factor XII, Inter-alpha-trypsin inhibitor heavy chain H3, Heparin cofactor 2, Coagulation factor X, Clusterin, Thrombospondin-1, and Prothrombin, wherein said at least one protein comprises Vitamin K-dependent protein S, in a sample from the subject,
- (b) determining that the subject has endometriosis based on the expression level;
- and
- (c) administering to the subject an endometriosis treatment selected from hormone therapy, hormonal contraceptives, androgenic agents, Gonadotropin-releasing hormone (Gn-RH) agonists and antagonists, progestin therapy, aromatase inhibitors, and surgery.
Dependencies are inferred from the claim text.